128:@0.085158:0.957873:0.109689:0.957873:0.109689:0.938882:0.085158:0.938882:0.007346:0.008593:0.008591
5:@0.038824:0.435294:0.060302:0.435294:0.060302:0.387816:0.038824:0.387816:0.021478
CHAPTER 5:@0.117647:0.067219:0.190589:0.067219:0.190589:0.047140:0.117647:0.047140:0.009172:0.009650:0.008799:0.008861:0.007388:0.007906:0.009359:0.003320:0.008487
Monitoring treatment response in patients with prostate cancer:@0.117647:0.122511:0.696112:0.122511:0.696112:0.099351:0.117647:0.099351:0.014817:0.011256:0.011679:0.004856:0.008516:0.011256:0.011231:0.004856:0.011679:0.011206:0.003984:0.008616:0.011231:0.009363:0.009460:0.008616:0.014817:0.009363:0.011679:0.008367:0.003984:0.011231:0.009211:0.010409:0.010733:0.011256:0.011679:0.010409:0.009363:0.003984:0.004856:0.011679:0.003984:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008514:0.010409:0.003738:0.015987:0.004856:0.008616:0.011579:0.003984:0.010733:0.011079:0.011256:0.010309:0.007520:0.009463:0.008616:0.009363:0.003984:0.010907:0.010558:0.011679:0.011007:0.009363:0.011231
In addition to the detection of SVs in cfDNA at baseline and progression of disease, we :@0.117647:0.164434:0.857066:0.164434:0.857066:0.144061:0.117647:0.144061:0.006894:0.011756:0.004805:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011756:0.004805:0.006211:0.011048:0.004805:0.006620:0.011299:0.009039:0.004805:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004805:0.010843:0.006209:0.004805:0.010112:0.015089:0.007670:0.004816:0.005615:0.011756:0.004805:0.008994:0.006209:0.015773:0.015408:0.014929:0.004805:0.008811:0.006437:0.004805:0.011117:0.009291:0.007875:0.008948:0.005250:0.005615:0.011596:0.009039:0.004805:0.009085:0.011596:0.011391:0.004816:0.011071:0.007442:0.011048:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.004805:0.010843:0.006209:0.004805:0.011391:0.005615:0.007875:0.009291:0.009291:0.007875:0.008743:0.004497:0.004805:0.014518:0.009039:0.004109
explored the capacity to use SVs to monitor treatment response over time. To enable re-:@0.117647:0.185013:0.852941:0.185013:0.852941:0.164640:0.117647:0.164640:0.009108:0.010089:0.011162:0.005182:0.010843:0.007442:0.009108:0.011391:0.004314:0.006620:0.011299:0.009039:0.004314:0.009108:0.008811:0.011368:0.009291:0.008994:0.005273:0.006437:0.009724:0.004314:0.006209:0.011048:0.004314:0.011413:0.007875:0.009039:0.004314:0.010112:0.015089:0.007670:0.004314:0.006209:0.011048:0.004314:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.004314:0.006437:0.007442:0.009288:0.008813:0.006437:0.017485:0.009039:0.011391:0.006437:0.004314:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004314:0.010866:0.009633:0.009039:0.007807:0.004314:0.006437:0.005615:0.017485:0.008743:0.004497:0.004314:0.010866:0.011048:0.004314:0.009039:0.011687:0.009108:0.010911:0.005182:0.009039:0.004314:0.007442:0.009060:0.007533
liable response monitoring, measurements should be accurate and repeatable. As VAFs :@0.117647:0.205592:0.856981:0.205592:0.856981:0.185219:0.117647:0.185219:0.005250:0.005798:0.009108:0.010911:0.005182:0.009039:0.004931:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.004931:0.017485:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009679:0.004497:0.004931:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.017485:0.009039:0.011391:0.006437:0.007670:0.004931:0.007556:0.011299:0.010820:0.011550:0.005182:0.011391:0.004931:0.011254:0.009039:0.004931:0.009291:0.008994:0.009108:0.011413:0.007898:0.008811:0.006209:0.009039:0.004931:0.009085:0.011596:0.011391:0.004931:0.007442:0.009131:0.011505:0.009288:0.008813:0.006549:0.009108:0.010911:0.005182:0.008743:0.004497:0.004931:0.014586:0.007670:0.004931:0.012578:0.014929:0.011276:0.007670:0.004109
are ratios and in principle not influenced by technical variations between timepoints, we :@0.117647:0.226170:0.857073:0.226170:0.857073:0.205797:0.117647:0.205797:0.009085:0.007442:0.009039:0.003881:0.007898:0.008811:0.006437:0.005547:0.010957:0.007670:0.003881:0.009085:0.011598:0.011391:0.003881:0.005615:0.011756:0.003881:0.011071:0.007807:0.005615:0.011596:0.008994:0.005271:0.011165:0.005182:0.009039:0.003881:0.011596:0.010820:0.006437:0.003881:0.005615:0.011756:0.005638:0.005296:0.011345:0.009039:0.011596:0.008994:0.009108:0.011391:0.003881:0.010843:0.009724:0.003881:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.009108:0.009405:0.005250:0.003881:0.009838:0.009085:0.007807:0.005798:0.008811:0.006437:0.005545:0.010845:0.011619:0.007670:0.003881:0.011254:0.009128:0.006437:0.014518:0.009106:0.009039:0.011756:0.003881:0.006437:0.005615:0.017485:0.009131:0.011505:0.010843:0.005615:0.011391:0.006437:0.007670:0.004497:0.003881:0.014518:0.009039:0.004109
chose to report VAFs only. To verify the accuracy of dPCR, we performed two technical :@0.117647:0.246749:0.857100:0.246749:0.857100:0.226376:0.117647:0.226376:0.008765:0.011299:0.010957:0.007875:0.009039:0.004360:0.006209:0.011048:0.004360:0.007442:0.009131:0.011505:0.010843:0.007967:0.006437:0.004360:0.012578:0.014929:0.011276:0.007670:0.004360:0.010843:0.011870:0.005182:0.007989:0.004497:0.004360:0.010866:0.011048:0.004360:0.009635:0.009039:0.007807:0.005615:0.006503:0.009724:0.004360:0.006620:0.011299:0.009039:0.004360:0.009291:0.008994:0.009108:0.011413:0.007898:0.009291:0.009382:0.009724:0.004360:0.010843:0.006209:0.004360:0.011391:0.012167:0.014678:0.013696:0.004497:0.004360:0.014520:0.009039:0.004360:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.004360:0.006437:0.014518:0.011048:0.004360:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.009108:0.009405:0.005250:0.004109
replicates for all pre-amplified samples of Pros5 and Pros6 and confirmed a high correla-:@0.117647:0.267328:0.852941:0.267328:0.852941:0.246955:0.117647:0.246955:0.007442:0.009131:0.011162:0.005250:0.005547:0.009108:0.008811:0.006209:0.009039:0.007670:0.003675:0.006026:0.010843:0.007807:0.003675:0.009405:0.005387:0.005250:0.003675:0.011071:0.007442:0.009039:0.007533:0.009085:0.017280:0.011162:0.005250:0.005615:0.005684:0.005615:0.009108:0.011391:0.003675:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.003675:0.010843:0.006209:0.003675:0.011913:0.007444:0.010957:0.007670:0.010432:0.003675:0.009085:0.011596:0.011391:0.003675:0.011916:0.007442:0.010957:0.007670:0.010432:0.003675:0.009085:0.011596:0.011391:0.003675:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017488:0.009106:0.011391:0.003675:0.009291:0.003675:0.011459:0.005615:0.009930:0.011459:0.003675:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.009265:0.007533
tion of VAFs between the replicates (r = 0.987, regression coefficient = 0.918) (:@0.117647:0.287906:0.796037:0.287906:0.796037:0.267534:0.117647:0.267534:0.006437:0.005547:0.010843:0.011756:0.006003:0.010843:0.006209:0.006003:0.012578:0.014929:0.011276:0.007670:0.006003:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.006003:0.006620:0.011299:0.009039:0.006003:0.007442:0.009131:0.011162:0.005250:0.005547:0.009108:0.008811:0.006209:0.009039:0.007670:0.006003:0.006939:0.007807:0.007739:0.011779:0.006003:0.010432:0.004497:0.010432:0.010432:0.010432:0.004497:0.006003:0.007442:0.009039:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.006003:0.008994:0.011276:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.006003:0.011779:0.006003:0.010432:0.004497:0.010432:0.010432:0.010432:0.006939:0.006003:0.006939
s :@0.443842:0.291059:0.450709:0.291059:0.450709:0.279182:0.443842:0.279182:0.004472:0.002395
Suppl. :@0.795989:0.287906:0.856957:0.287906:0.856957:0.266774:0.795989:0.266774:0.010455:0.011893:0.011733:0.011779:0.005659:0.005433:0.004018
Figure 9C:@0.117647:0.308485:0.207059:0.308485:0.207059:0.287352:0.117647:0.287352:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005547:0.010911:0.014769
). Finally, we quantified the eight SVs of the four prostate cancer patients in :@0.207062:0.308485:0.857142:0.308485:0.857142:0.288112:0.207062:0.288112:0.006939:0.004497:0.005684:0.011388:0.005615:0.011687:0.009405:0.005387:0.005182:0.007989:0.004497:0.005684:0.014518:0.009039:0.005684:0.010706:0.011596:0.009085:0.011391:0.006437:0.005615:0.005684:0.005615:0.009108:0.011391:0.005684:0.006620:0.011299:0.009039:0.005684:0.009039:0.005615:0.009927:0.011094:0.006437:0.005684:0.010112:0.015089:0.007670:0.005684:0.010843:0.006209:0.005684:0.006620:0.011299:0.009039:0.005684:0.006024:0.010822:0.011413:0.007807:0.005684:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.005684:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.005684:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005684:0.005615:0.011756:0.004109
the longitudinally collected samples from before, during and after treatment. For Pros1, :@0.117647:0.329064:0.857048:0.329064:0.857048:0.308691:0.117647:0.308691:0.006620:0.011299:0.009039:0.004543:0.005182:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005387:0.005182:0.009724:0.004543:0.008994:0.010934:0.005387:0.005182:0.009108:0.009108:0.006209:0.009108:0.011391:0.004543:0.007944:0.009085:0.017280:0.011162:0.005182:0.009039:0.007670:0.004543:0.006412:0.007442:0.010843:0.017645:0.004543:0.011254:0.009039:0.006026:0.010843:0.007442:0.008743:0.004497:0.004543:0.011048:0.011413:0.007807:0.005615:0.011459:0.009861:0.004543:0.009085:0.011596:0.011391:0.004543:0.009085:0.006197:0.005969:0.009039:0.007807:0.004543:0.006437:0.007442:0.009288:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.004543:0.010683:0.010843:0.007807:0.004543:0.011916:0.007442:0.010957:0.007670:0.010432:0.004497:0.004109
SV-A shows the potential to improve response evaluation as its dynamics correspond :@0.117647:0.349643:0.857141:0.349643:0.857141:0.329270:0.117647:0.329270:0.010112:0.013308:0.007533:0.014929:0.006186:0.007556:0.011299:0.010866:0.014723:0.007670:0.006186:0.006620:0.011299:0.009039:0.006186:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009402:0.005250:0.006186:0.006209:0.011048:0.006186:0.005615:0.017280:0.011071:0.007442:0.010866:0.009633:0.009039:0.006186:0.007442:0.009039:0.007512:0.011502:0.010843:0.011621:0.007873:0.009039:0.006186:0.009336:0.009838:0.009402:0.004908:0.011596:0.008811:0.006437:0.005547:0.010843:0.011756:0.006186:0.009291:0.007670:0.006186:0.005273:0.006437:0.007670:0.006186:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.006186:0.008994:0.010843:0.007807:0.007442:0.009039:0.007512:0.011502:0.010843:0.011598:0.011391:0.004109
to the expected response to treatment with cabazitaxel and increases towards the end of :@0.117647:0.370221:0.857093:0.370221:0.857093:0.349848:0.117647:0.349848:0.006209:0.011048:0.004428:0.006620:0.011299:0.009039:0.004428:0.009108:0.010089:0.011502:0.009108:0.009108:0.006209:0.009108:0.011391:0.004428:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007875:0.009039:0.004428:0.006209:0.011048:0.004428:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004428:0.014723:0.005273:0.006617:0.011459:0.004428:0.009108:0.009108:0.011117:0.009291:0.008834:0.005273:0.006549:0.009291:0.009884:0.008948:0.005250:0.004428:0.009085:0.011596:0.011391:0.004428:0.005615:0.011596:0.008994:0.007442:0.009291:0.009291:0.007875:0.009039:0.007670:0.004428:0.006211:0.010863:0.014723:0.009085:0.007442:0.011391:0.007670:0.004428:0.006620:0.011299:0.009039:0.004428:0.009039:0.011598:0.011391:0.004428:0.010843:0.006209:0.004109
treatment, resulting in the highest levels at clinical progression of disease (:@0.117647:0.390800:0.754145:0.390800:0.754145:0.370427:0.117647:0.370427:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.005844:0.007442:0.009039:0.007510:0.011550:0.004908:0.006437:0.005615:0.011459:0.009861:0.005844:0.005615:0.011756:0.005844:0.006620:0.011299:0.009039:0.005844:0.011459:0.005615:0.009927:0.011299:0.009039:0.007510:0.006437:0.005844:0.005184:0.009334:0.009633:0.008948:0.005250:0.007670:0.005844:0.008811:0.006437:0.005844:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.005844:0.011071:0.007442:0.011048:0.009861:0.007442:0.009039:0.007533:0.007601:0.005547:0.010843:0.011756:0.005844:0.010843:0.006209:0.005844:0.011391:0.005615:0.007873:0.009291:0.009291:0.007875:0.009039:0.005844:0.006939
Figure 4E:@0.754246:0.390800:0.841513:0.390800:0.841513:0.369667:0.754246:0.369667:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005730:0.010911:0.012441
). :@0.841505:0.390800:0.857050:0.390800:0.857050:0.370427:0.841505:0.370427:0.006939:0.004497:0.004109
These changes also seem to correlate with other blood biomarkers, including PSA and :@0.117647:0.411379:0.857073:0.411379:0.857073:0.391006:0.117647:0.391006:0.011470:0.011311:0.009039:0.007875:0.009039:0.005615:0.008765:0.011391:0.009085:0.011459:0.009658:0.009039:0.007670:0.005615:0.009405:0.005250:0.007873:0.011048:0.005615:0.007875:0.009108:0.009039:0.017645:0.005615:0.006209:0.011048:0.005615:0.008994:0.010843:0.007807:0.007442:0.008948:0.005430:0.008813:0.006207:0.009039:0.005615:0.014723:0.005271:0.006620:0.011459:0.005615:0.010820:0.006620:0.011299:0.009039:0.007807:0.005615:0.010911:0.005182:0.011276:0.011276:0.011391:0.005615:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.004497:0.005615:0.005615:0.011596:0.008765:0.004908:0.011345:0.011391:0.005615:0.011459:0.009861:0.005615:0.012167:0.010112:0.014929:0.005615:0.009085:0.011598:0.011391:0.004109
ALP. In addition, SV-B in Pros1 similarly correlates with response to treatment (:@0.117647:0.431957:0.794708:0.431957:0.794708:0.411584:0.117647:0.411584:0.014929:0.011619:0.008811:0.004497:0.004839:0.006894:0.011756:0.004839:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011756:0.004497:0.004839:0.010112:0.013308:0.007533:0.012646:0.004839:0.005615:0.011756:0.004839:0.011916:0.007442:0.010957:0.007670:0.010432:0.004839:0.007601:0.005615:0.017645:0.005750:0.005433:0.009085:0.007601:0.005182:0.009724:0.004839:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006209:0.009039:0.007670:0.004839:0.014723:0.005273:0.006620:0.011459:0.004839:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004839:0.006209:0.011048:0.004839:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004839:0.006939
Figure :@0.794756:0.431957:0.856959:0.431957:0.856959:0.410825:0.794756:0.410825:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018
4E:@0.117647:0.452536:0.140999:0.452536:0.140999:0.431403:0.117647:0.431403:0.010911:0.012441
). Also for Pros5 both SV-A and SV-B show clear changes over time correlating with :@0.140999:0.452536:0.857048:0.452536:0.857048:0.432163:0.140999:0.432163:0.006939:0.004497:0.004942:0.015066:0.005250:0.007875:0.011048:0.004940:0.006026:0.010843:0.007807:0.004942:0.011916:0.007442:0.010957:0.007670:0.010432:0.004942:0.011254:0.010820:0.006620:0.011459:0.004942:0.010112:0.013308:0.007533:0.014929:0.004942:0.009085:0.011596:0.011391:0.004942:0.010112:0.013308:0.007533:0.012646:0.004942:0.007556:0.011299:0.010866:0.014723:0.004942:0.008765:0.005182:0.009291:0.009085:0.007807:0.004942:0.008765:0.011391:0.009085:0.011459:0.009656:0.009039:0.007670:0.004942:0.010866:0.009633:0.009039:0.007807:0.004942:0.006437:0.005615:0.017485:0.009039:0.004942:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005615:0.011459:0.009861:0.004942:0.014723:0.005271:0.006620:0.011459:0.004109
clinical parameters, and Pros4 and Pros6 have less compelling dynamics of the detected :@0.117647:0.473115:0.857032:0.473115:0.857032:0.452742:0.117647:0.452742:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.004474:0.011368:0.009085:0.007898:0.009085:0.017485:0.009131:0.006209:0.009039:0.007624:0.007670:0.004497:0.004474:0.009085:0.011596:0.011391:0.004474:0.011916:0.007442:0.010957:0.007670:0.010432:0.004474:0.009085:0.011598:0.011391:0.004474:0.011916:0.007442:0.010957:0.007670:0.010432:0.004474:0.011391:0.008925:0.009633:0.009039:0.004474:0.005182:0.009039:0.007533:0.007670:0.004474:0.008994:0.010843:0.017280:0.011505:0.008948:0.005387:0.005250:0.005615:0.011459:0.009861:0.004474:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.004474:0.010843:0.006209:0.004474:0.006620:0.011299:0.009039:0.004474:0.011322:0.009131:0.006211:0.009106:0.009108:0.006209:0.009108:0.011391:0.004109
SVs (:@0.117647:0.493694:0.161566:0.493694:0.161566:0.473321:0.117647:0.473321:0.010112:0.015089:0.007670:0.004109:0.006939
Suppl. Figure 10A-C:@0.161565:0.493694:0.342899:0.493694:0.342899:0.472561:0.161565:0.472561:0.010455:0.011893:0.011733:0.011779:0.005661:0.005433:0.004018:0.011596:0.006209:0.010749:0.011893:0.008263:0.009473:0.004018:0.010911:0.010911:0.014358:0.007213:0.014769
). :@0.342899:0.493694:0.358444:0.493694:0.358444:0.473321:0.342899:0.473321:0.006939:0.004497:0.004109
Discussion:@0.117647:0.571347:0.232229:0.571347:0.232229:0.543237:0.117647:0.543237:0.013103:0.006217:0.012144:0.012841:0.013015:0.012144:0.012144:0.006217:0.013132:0.013626
Recent studies have utilized somatic SVs for tracking tumor burden from liquid biop-:@0.117647:0.613197:0.852941:0.613197:0.852941:0.592824:0.117647:0.592824:0.013696:0.009108:0.008994:0.009039:0.011391:0.006437:0.005684:0.007510:0.006163:0.011345:0.011391:0.005547:0.009039:0.007670:0.005684:0.011391:0.008925:0.009633:0.009039:0.005684:0.011071:0.006437:0.005752:0.005250:0.005615:0.008834:0.009106:0.011391:0.005684:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.005684:0.010112:0.015089:0.007670:0.005684:0.006024:0.010845:0.007807:0.005684:0.006437:0.007898:0.009291:0.008765:0.010706:0.005615:0.011459:0.009861:0.005684:0.006163:0.011413:0.017485:0.010843:0.007807:0.005684:0.010797:0.011413:0.007442:0.011322:0.009039:0.011756:0.005684:0.006414:0.007442:0.010843:0.017645:0.005684:0.005250:0.005547:0.010706:0.011413:0.005547:0.011391:0.005684:0.010820:0.005547:0.010820:0.011254:0.007533
sies:@0.117647:0.633776:0.147504:0.633776:0.147504:0.613403:0.117647:0.613403:0.007601:0.005547:0.009039:0.007670
69,165,166,357:@0.147504:0.626160:0.222269:0.626160:0.222269:0.614282:0.147504:0.614282:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. Although these studies showed the potential of this methodology, they :@0.222266:0.633776:0.857100:0.633776:0.857100:0.613403:0.222266:0.613403:0.004497:0.007190:0.015066:0.004908:0.006620:0.011299:0.010820:0.011413:0.009930:0.011459:0.007190:0.006617:0.011302:0.009039:0.007873:0.009039:0.007190:0.007510:0.006163:0.011347:0.011391:0.005545:0.009039:0.007670:0.007190:0.007556:0.011299:0.010866:0.014518:0.009108:0.011391:0.007190:0.006620:0.011299:0.009039:0.007190:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.007190:0.010843:0.006209:0.007190:0.006620:0.011459:0.005615:0.007670:0.007190:0.017485:0.009131:0.006620:0.011299:0.011276:0.011322:0.010934:0.005182:0.011048:0.010546:0.007989:0.004497:0.007190:0.006620:0.011299:0.009336:0.009724:0.004109
lacked sufficient turn-around time to provide personalized biomarkers before the ini-:@0.117647:0.654354:0.852941:0.654354:0.852941:0.633981:0.117647:0.633981:0.005433:0.009291:0.008765:0.010272:0.009108:0.011391:0.006095:0.007510:0.011413:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006437:0.006095:0.006163:0.011413:0.007807:0.011756:0.007533:0.009085:0.007442:0.010820:0.011413:0.011596:0.011391:0.006095:0.006437:0.005615:0.017485:0.009039:0.006095:0.006209:0.011048:0.006095:0.011071:0.007442:0.010866:0.009838:0.005547:0.011322:0.009039:0.006095:0.011502:0.009039:0.007624:0.007875:0.010843:0.011687:0.009405:0.005250:0.005615:0.008834:0.009108:0.011391:0.006095:0.010820:0.005547:0.010843:0.017577:0.009085:0.007601:0.010272:0.009039:0.007624:0.007670:0.006095:0.011254:0.009039:0.006026:0.010843:0.007442:0.009039:0.006095:0.006620:0.011299:0.009039:0.006095:0.005615:0.011756:0.005615:0.007533
tiation of patient treatment. This is due to lengthy short-read WGS approaches for SV :@0.117647:0.674933:0.856936:0.674933:0.856936:0.654560:0.117647:0.654560:0.006437:0.005798:0.008811:0.006437:0.005547:0.010843:0.011756:0.005730:0.010843:0.006209:0.005730:0.011365:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.005730:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.004497:0.005730:0.011470:0.011470:0.005615:0.007670:0.005730:0.005615:0.007670:0.005730:0.011048:0.011345:0.009039:0.005730:0.006209:0.011048:0.005730:0.005182:0.009039:0.011459:0.009861:0.006620:0.011071:0.009724:0.005730:0.007556:0.011299:0.010843:0.007967:0.006437:0.007533:0.007442:0.009291:0.009291:0.011391:0.005730:0.020270:0.015682:0.010112:0.005730:0.008811:0.011048:0.011071:0.007442:0.011139:0.009291:0.008765:0.011299:0.009039:0.007670:0.005730:0.006026:0.010843:0.007807:0.005730:0.010112:0.015089:0.004109
detection and an associated substantial number of false-positive somatic SVs, requiring :@0.117647:0.695512:0.857096:0.695512:0.857096:0.675139:0.117647:0.675139:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.004634:0.009085:0.011596:0.011391:0.004634:0.009085:0.011756:0.004634:0.009291:0.007533:0.007873:0.011276:0.008994:0.005798:0.008811:0.006209:0.009108:0.011391:0.004634:0.007510:0.011345:0.010934:0.007510:0.006551:0.009085:0.011391:0.006437:0.005798:0.009405:0.005250:0.004634:0.011391:0.011413:0.017394:0.011254:0.009039:0.007807:0.004634:0.010843:0.006209:0.004634:0.006209:0.009405:0.005250:0.007875:0.009039:0.007533:0.011505:0.010957:0.007601:0.005273:0.006437:0.005545:0.009635:0.009039:0.004634:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004634:0.010112:0.015089:0.007670:0.004497:0.004634:0.007442:0.009108:0.010706:0.011413:0.005615:0.007807:0.005615:0.011459:0.009861:0.004109
laborious testing to validate SVs. To overcome these limitations, we utilized the real-time :@0.117647:0.716090:0.857150:0.716090:0.857150:0.695718:0.117647:0.695718:0.005433:0.009108:0.011254:0.010843:0.007807:0.005547:0.010820:0.011413:0.007670:0.003561:0.006209:0.009039:0.007510:0.006437:0.005615:0.011459:0.009861:0.003561:0.006209:0.011048:0.003561:0.009838:0.009402:0.005250:0.005547:0.011573:0.008811:0.006209:0.009039:0.003561:0.010112:0.015089:0.007670:0.004497:0.003561:0.010866:0.011048:0.003561:0.010866:0.009633:0.009039:0.007442:0.008994:0.010843:0.017485:0.009039:0.003561:0.006620:0.011299:0.009039:0.007875:0.009039:0.003561:0.005250:0.005615:0.017645:0.005273:0.006551:0.008811:0.006437:0.005545:0.010845:0.011619:0.007670:0.004497:0.003550:0.014518:0.009039:0.003561:0.011071:0.006437:0.005752:0.005250:0.005615:0.008834:0.009108:0.011391:0.003561:0.006620:0.011299:0.009039:0.003561:0.007442:0.009291:0.009402:0.005250:0.007533:0.006437:0.005615:0.017485:0.009039:0.004109
and long-read capabilities of nanopore sequencing combined with a machine learning :@0.117647:0.736669:0.856959:0.736669:0.856959:0.716296:0.117647:0.716296:0.009085:0.011596:0.011391:0.005547:0.005182:0.010843:0.011459:0.009861:0.007533:0.007442:0.009291:0.009291:0.011391:0.005547:0.009108:0.008811:0.011368:0.009108:0.010820:0.005750:0.005250:0.005273:0.006437:0.005547:0.009039:0.007670:0.005547:0.010843:0.006209:0.005547:0.011687:0.009085:0.011596:0.010822:0.011502:0.010843:0.007442:0.009039:0.005547:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.005547:0.008994:0.010843:0.017394:0.010820:0.005615:0.011596:0.009108:0.011391:0.005547:0.014723:0.005273:0.006620:0.011459:0.005547:0.009291:0.005547:0.017577:0.009291:0.008765:0.011459:0.005615:0.011596:0.009039:0.005547:0.005182:0.009291:0.009085:0.007807:0.011756:0.005615:0.011459:0.009861:0.004109
approach to efficiently identify a set of somatic SVs from tumor tissue within three days. :@0.117647:0.757248:0.857144:0.757248:0.857144:0.736875:0.117647:0.736875:0.008811:0.011048:0.011071:0.007442:0.011139:0.009291:0.008765:0.011459:0.004086:0.006209:0.011048:0.004086:0.009039:0.005692:0.005692:0.005623:0.008994:0.005547:0.009039:0.011391:0.006620:0.005182:0.009724:0.004086:0.005547:0.011322:0.009039:0.011393:0.006437:0.005615:0.006503:0.009724:0.004086:0.009291:0.004086:0.007875:0.009128:0.006437:0.004086:0.010843:0.006209:0.004086:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004086:0.010112:0.015089:0.007670:0.004086:0.006414:0.007442:0.010843:0.017645:0.004086:0.006163:0.011413:0.017488:0.010843:0.007807:0.004086:0.006437:0.005615:0.007533:0.007510:0.011345:0.009039:0.004086:0.014723:0.005273:0.006620:0.011459:0.005615:0.011756:0.004086:0.006620:0.011459:0.007442:0.009108:0.009039:0.004086:0.011573:0.008925:0.009724:0.007670:0.004497:0.004109
The rapid and simple workflow offers great potential for routine monitoring of cancer :@0.117647:0.777827:0.857134:0.777827:0.857134:0.757454:0.117647:0.757454:0.011470:0.011311:0.009039:0.005775:0.007898:0.008811:0.011071:0.005547:0.011391:0.005775:0.009085:0.011596:0.011391:0.005775:0.007601:0.005615:0.017280:0.011162:0.005182:0.009039:0.005764:0.014518:0.010843:0.007601:0.010706:0.005638:0.005570:0.010866:0.014723:0.005775:0.010843:0.005969:0.005787:0.009039:0.007624:0.007670:0.005775:0.009861:0.007442:0.009291:0.008811:0.006437:0.005764:0.011505:0.010820:0.006209:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.005775:0.006026:0.010843:0.007807:0.005775:0.007442:0.010820:0.011071:0.006437:0.005615:0.011596:0.009039:0.005764:0.017488:0.010843:0.011756:0.005273:0.006209:0.010843:0.007807:0.005615:0.011459:0.009861:0.005775:0.010843:0.006209:0.005775:0.009108:0.009085:0.011596:0.008994:0.009039:0.007807:0.004109
dynamics. We illustrate the applicability of our method to measure tumor burden by :@0.117647:0.798405:0.857050:0.798405:0.857050:0.778032:0.117647:0.778032:0.011322:0.009724:0.011687:0.009085:0.017645:0.005547:0.008994:0.007670:0.004497:0.006563:0.018649:0.009039:0.006563:0.005752:0.005387:0.004908:0.011413:0.007510:0.006437:0.007898:0.008811:0.006209:0.009039:0.006563:0.006617:0.011302:0.009039:0.006563:0.008811:0.011048:0.011162:0.005250:0.005547:0.009106:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.006563:0.010843:0.006209:0.006563:0.010820:0.011413:0.007807:0.006563:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.006563:0.006209:0.011048:0.006563:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009039:0.006563:0.006163:0.011413:0.017485:0.010843:0.007807:0.006563:0.010797:0.011413:0.007442:0.011322:0.009039:0.011756:0.006563:0.010843:0.009724:0.004109
using a series of longitudinally gathered blood samples from metastatic prostate cancer :@0.117647:0.818984:0.857121:0.818984:0.857121:0.798611:0.117647:0.798611:0.011413:0.007601:0.005615:0.011459:0.009861:0.004976:0.009291:0.004976:0.007875:0.009039:0.007807:0.005545:0.009039:0.007670:0.004976:0.010843:0.006209:0.004976:0.005182:0.010843:0.011459:0.009861:0.005273:0.006163:0.011345:0.011391:0.005615:0.011687:0.009405:0.005387:0.005182:0.009724:0.004976:0.009861:0.008811:0.006620:0.011299:0.009039:0.007442:0.009108:0.011391:0.004976:0.010911:0.005182:0.011276:0.011276:0.011391:0.004976:0.007941:0.009087:0.017280:0.011160:0.005184:0.009039:0.007670:0.004976:0.006414:0.007442:0.010843:0.017645:0.004976:0.017485:0.009131:0.006551:0.009291:0.007510:0.006551:0.008811:0.006437:0.005547:0.008994:0.004976:0.011071:0.007442:0.010957:0.007510:0.006551:0.008811:0.006209:0.009039:0.004976:0.009108:0.009087:0.011596:0.008994:0.009039:0.007807:0.004109
patients. :@0.117647:0.839563:0.192953:0.839563:0.192953:0.819190:0.117647:0.819190:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.004497:0.004109
Obtaining enough tumor material for DNA isolation is often a limiting factor for :@0.117647:0.860141:0.856959:0.860141:0.856959:0.839768:0.117647:0.839768:0.016412:0.010797:0.006551:0.009085:0.005615:0.011756:0.005615:0.011459:0.009861:0.009039:0.009039:0.011596:0.010820:0.011413:0.009930:0.011459:0.009039:0.006163:0.011413:0.017485:0.010843:0.007807:0.009039:0.017577:0.008811:0.006209:0.009039:0.007807:0.005798:0.009402:0.005250:0.009039:0.006026:0.010843:0.007807:0.009039:0.015773:0.015408:0.014929:0.009039:0.005615:0.007875:0.010934:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.009039:0.005615:0.007670:0.009039:0.010843:0.006197:0.005969:0.009039:0.011756:0.009039:0.009291:0.009039:0.005250:0.005615:0.017645:0.005273:0.006437:0.005615:0.011459:0.009861:0.009039:0.006209:0.009291:0.009108:0.006209:0.010843:0.007807:0.009039:0.006024:0.010845:0.007807:0.004109
next-generation sequencing assays. We show that nanopore sequencing and somatic SV :@0.117647:0.880720:0.857139:0.880720:0.857139:0.860347:0.117647:0.860347:0.011596:0.009108:0.010089:0.006437:0.007533:0.009656:0.009039:0.011596:0.009039:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.004246:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004246:0.009291:0.007531:0.007944:0.008925:0.009724:0.007670:0.004497:0.004246:0.018649:0.009039:0.004246:0.007556:0.011299:0.010866:0.014723:0.004246:0.006620:0.011391:0.008811:0.006437:0.004246:0.011687:0.009087:0.011596:0.010820:0.011502:0.010843:0.007442:0.009039:0.004246:0.007873:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004246:0.009085:0.011598:0.011391:0.004246:0.007875:0.010843:0.017577:0.008811:0.006437:0.005547:0.008994:0.004246:0.010112:0.015089:0.004109
detection is possible from limited amounts of DNA that can be extracted from a meta-:@0.117647:0.901299:0.852941:0.901299:0.852941:0.880926:0.117647:0.880926:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.005022:0.005615:0.007670:0.005022:0.011505:0.010957:0.007533:0.007601:0.005547:0.010911:0.005182:0.009039:0.005022:0.006414:0.007442:0.010843:0.017645:0.005022:0.005250:0.005615:0.017645:0.005271:0.006209:0.009108:0.011391:0.005022:0.009085:0.017485:0.010820:0.011413:0.011391:0.006437:0.007670:0.005022:0.010843:0.006209:0.005022:0.015773:0.015408:0.014929:0.005022:0.006620:0.011391:0.008811:0.006437:0.005022:0.009108:0.009085:0.011756:0.005022:0.011254:0.009039:0.005022:0.009108:0.010089:0.006437:0.007898:0.009291:0.009106:0.006211:0.009106:0.011391:0.005022:0.006412:0.007442:0.010845:0.017645:0.005022:0.009291:0.005022:0.017485:0.009131:0.006551:0.009201:0.007533
static tumor needle biopsy, which is an important requisite for clinical viability. DNA in-:@0.117647:0.921878:0.852941:0.921878:0.852941:0.901505:0.117647:0.901505:0.007510:0.006551:0.008811:0.006437:0.005547:0.008994:0.003938:0.006163:0.011413:0.017485:0.010843:0.007807:0.003938:0.011596:0.009108:0.009108:0.011525:0.005182:0.009039:0.003938:0.010820:0.005547:0.010820:0.011185:0.007761:0.007989:0.004497:0.003938:0.014792:0.011459:0.005547:0.008765:0.011459:0.003935:0.005615:0.007670:0.003938:0.009085:0.011756:0.003938:0.005615:0.017280:0.011502:0.010845:0.007964:0.006551:0.009085:0.011391:0.006437:0.003938:0.007442:0.009108:0.010706:0.011413:0.005615:0.007601:0.005273:0.006209:0.009039:0.003938:0.006024:0.010845:0.007807:0.003935:0.008765:0.005250:0.005615:0.011756:0.005547:0.009108:0.009405:0.005250:0.003938:0.009838:0.005798:0.009108:0.010818:0.005752:0.005250:0.005273:0.006437:0.007989:0.004497:0.003938:0.015773:0.015408:0.014929:0.003938:0.005615:0.011754:0.007533